**INTRODUCTION**

- Heart failure with preserved ejection fraction (HFpEF) is associated with high morbidity and mortality, and remains a major health concern.
- TN-301 (TEN-11531) is a highly selective inhibitor of histone deacetylase 6 (HDAC6), an important protein involved in cellular processes.
- Assessment of HDAC6 inhibition in multiple preclinical models has demonstrated cardio-protective properties, with a distinct, mechanism-independent activity, including direct effects on the heart and systemic effects on pathways linked to HFpEF pathophysiology.

**METHODS**

- **Study Participants**: Healthy adults (women and infertile men*), 18 – 60 years of age, with informed consent.
- **Study Design**: This was a 2-stage randomized, blinded, placebo-controlled study.
- **Phase 1 Clinical Trial of TN-301**: A Phase 1/2 clinical trial of TN-301, a highly selective HDAC6 inhibitor with potential in heart failure with preserved ejection fraction (HFpEF), shows target engagement.

**RESULTS**

- The study was conducted per protocol, at a single US site.
- **Clinical Safety and Tolerability of TN-301**: The study was well tolerated at doses up to 700 mg.
- **Pharmacodynamics – SAD + MAD**: TN-301 plasma concentration, AUC, and 

**REFERENCES**

- **Clinical Safety and Tolerability of TN-301**: The study was well tolerated at doses up to 700 mg.
- **Pharmacodynamics – SAD + MAD**: TN-301 plasma concentration, AUC, and

**ACKNOWLEDGEMENTS**

We wish to thank the participants and their families for their contributions to this clinical trial.